Several small-molecule mitochondrial uncouplers have demonstrated anticancer effects in preclinical models, although endogenous UCPs—particularly UCP2—are often upregulated in tumors, where they may support tumor growth by buffering ROS and increasing metabolic flexibility. The gene discussed is UCP2; the disease is neoplasm.